Cancer cells acquire distinct metabolic preferences based on their tissue of origin, genetic
alterations and degree of interaction with systemic hormones and metabolites. These …

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but
an effective targeted therapy has not been well-established so far. Considering the lack of …

Ferroptosis therapy, which applies ferroptotic inducers to produce lethal lipid peroxidation
and induce the death of tumor cells, is regarded as a promising therapeutic strategy for …

Triple-negative breast cancer (TNBC) is an aggressive, difficult-to-treat subtype of cancer
with a poor prognosis; there is an urgent need for effective, targeted molecular therapies …

Triple-negative breast cancer (TNBC) is the most violent class of tumor and accounts for 20–
24% of total breast carcinoma, in which frequently rare mutation occurs in high frequency …

The formation of cyclinD-CDK4/6 complex plays vital roles in the cell cycle transition from G1
phase to S phase which is characterized by vigorous transcription and synthesis. Through …

Soy isoflavones are natural tyrosine kinase inhibitors closely associated with decreased
morbidity and mortality of various tumors. The activation of tyrosine kinases such as ERBB2 …

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast
cancer, marked by poor outcomes and dismal prognosis. Due to the absence of targetable …

ABSTRACT Palbociclib, a selective CDK4/6 kinase inhibitor, is approved in combination
with endocrine therapies for the treatment of advanced estrogen receptor positive (ER+) …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with
unfavorable outcomes. Developing therapeutic targets for TNBC remains a challenge. Here …